TherapeuticsMD (TXMD) recently released an investor presentation with updated IMVEXXY launch metrics. The slide presentation contained vital information regarding the company's ongoing launch efforts. Not only was the data contained within the presentation encouraging, but the fact management continues to update investors regularly throughout the IMVEXXY launch is reassuring.
The stock appears to have fully recovered from the end of 2018 sell-off. Since my last TXMD article, the share price has moved up from the low $4.00 range and has found a new home in the $5.00-5.50 per share area. In addition,